ASX stocks see significant shifts following mining discoveries and tech trials

In Wednesday’s morning trade, Australian Securities Exchange (ASX) stocks witnessed notable fluctuations. The primary winners were Golden State Mining (ASX:GSM), HeraMED (ASX:HMD), and New World Resources (ASX:NWC), while BOD Australia (ASX:BOD) faced a decline.

Golden State Mining experienced a 56% surge in its stock price following promising field mapping findings at its Paynes Find project in Western Australia. The discovery of pegmatite outcrops within lithium-caesium-tantalum geochemistry envelopes has sparked anticipation for rock chip assay results, which could confirm the presence of these valuable minerals.

HeraMED, a digital maternity care provider, saw its stock rise by 24%. This boost followed the initiation of a clinical trial involving 90 pregnancies at the Gold Coast Hospital. The trial aims to evaluate the usability, patient satisfaction, and economic implications of HeraMED’s technology, with the potential to improve maternity care significantly.

New World Resources secured an $11 million investment deal with Trident Royalties Plc for a 0.9% Net Smelter Return (NSR) royalty over its Antler Project in Arizona. This strategic deal is expected to enhance New World Resources’ exploration and development efforts, and positively impact its stock performance.

On the other hand, BOD Australia experienced an 11% fall in its stock price. This decrease came after the company announced firm commitments to raise $2.05 million through a two-tranche placement at 3 cents per share. The funds are intended to facilitate growth in the cannabis sector.

While these companies saw significant movements in their stock prices, others such as Adherium Ltd (ASX:ADR) and Avira Resources Ltd (ASX:AVW) also faced losses. This market volatility underlines the need for investor diligence in navigating the ASX.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.